Testing effectiveness (Phase 2)Study completedNCT00001031
What this trial is testing
A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults
Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 296